Abstract
Anti-CD38 monoclonal antibodies (mAbs) like daratumumab and isatuximab have revolutionized the treatment of multiple myeloma (MM). However, their clinical utility is hampered by CD38 expression on red blood cells (RBCs), leading to an "antigen sink" and interference with blood compatibility testing. We report the development of FTL004, a novel humanized anti-CD38 mAb that exhibits negligible binding to RBCs while maintaining high affinity for malignant cells. FTL004 demonstrates superior pro-apoptotic activity and enhanced antibody-dependent cellular cytotoxicity (ADCC) through Fc engineering. Structural analysis via cryo-electron microscopy reveals a unique epitope that distinguishes FTL004 from existing therapies. These findings suggest FTL004 is a promising candidate for treating MM and non-Hodgkin lymphoma with an improved safety and pharmacokinetic profile.
Introduction
The cell surface glycoprotein CD38 is highly expressed in multiple myeloma and various lymphomas, making it an ideal therapeutic target. While current anti-CD38 mAbs have shown significant success, they suffer from off-target binding to RBCs. This binding necessitates high dosing to overcome the "antigen sink" and complicates pre-transfusion testing due to RBC agglutination. FTL004 was designed to address these limitations by targeting a unique epitope that is less accessible or less prevalent on healthy RBCs, providing a "molecular stealth" advantage.
Methods
FTL004 is a humanized IgG1κ antibody. To maximize the immune system's "kill signal," the Fc domain was engineered with specific mutations (S240D/I333E) to increase affinity for Fcγ receptors on Natural Killer (NK) cells, boosting Antibody-Dependent Cellular Cytotoxicity (ADCC). The study employed surface plasmon resonance (SPR) for affinity measurements and flow cytometry for cell binding assays. Structural mapping was performed using Cryo-electron microscopy (Cryo-EM) at a resolution of 3.86 Å to identify the exact binding interface on the CD38 protein.
Results
FTL004 demonstrated high binding affinity (KD = 2.55 nM) comparable to clinical standards (Fig. 1a). Crucially, flow cytometry revealed that FTL004 binding to human RBCs was virtually undetectable, even at concentrations up to 30 μg/mL, whereas daratumumab and isatuximab showed significant binding (Fig. 1c). Furthermore, FTL004 did not induce RBC agglutination in indirect antiglobulin tests, potentially solving the blood transfusion interference issue common with current therapies (Fig. 1d).
Structural analysis identified two epitope centers for FTL004 on CD38. One center (91TQTV94) partially overlaps with the isatuximab epitope, while the other is entirely unique. Notably, FTL004 shares no common binding residues with daratumumab (Fig. 1h-j). This unique binding profile likely underlies the observed RBC-sparing effect.
Functionally, FTL004 induced significantly higher rates of direct apoptosis in MM cell lines compared to isatuximab. For instance, in RPMI 8226 cells, FTL004 induced 55% early apoptosis compared to just 20% for isatuximab. The engineered Fc domain resulted in high ADCC potency, with EC50 values in the low ng/mL range. In vivo, FTL004 effectively inhibited tumor growth in lymphoma and myeloma xenograft models compared to saline controls.
Discussion and Conclusion
FTL004 represents a significant advancement in anti-CD38 therapy. By avoiding RBC binding, it potentially eliminates the need for high-dose "loading" and simplifies clinical management of patients requiring blood transfusions. The combination of enhanced direct apoptosis and boosted ADCC suggests superior anti-tumor efficacy. While some NK cell depletion was observed—a common trait of anti-CD38 therapies—the levels were considered acceptable (Fig. 1g).
In conclusion, FTL004 is a potent, next-generation anti-CD38 mAb with a unique structural footprint. Its ability to discriminate between malignant cells and healthy RBCs, combined with enhanced immune-mediated killing, makes it a highly promising candidate for the treatment of CD38-positive hematological malignancies. Future clinical trials will be essential to confirm if these preclinical advantages translate into superior outcomes for patients.
Summary updated